| ||||||||||||||
|
|
|||||||||||||
Nuffield Department of Anaesthetics; University of Oxford; Oxford, UK; kyle.pattinson{at}nda.ox.ac.uk (Pattinson, Rogers) Oxford Centre for Functional MRI of the Brain; University of Oxford, UK (Mayhew, MacIntosh) Division of Anaesthesia; University of Cambridge, UK (Lee) CUBRIC, School of Psychology; Cardiff University, UK (Wise)
To the Editor:
A recent study by Kofke et al.1 assessing the effect of remifentanil on magnetic resonance imaging-measured cerebral blood flow (CBF) highlights the importance of determining whether CBF changes observed are due to opioid agonism or hypercapnic cerebral vasodilatation. In this study, normalization was used to account for the additional effect that hypercapnia has on CBF in an attempt to isolate the effects of opioid agonism. This assumption is reasonable providing the normalization factor takes into account regional heterogeneity of the CBF response to hypercapnia. Unfortunately, only a global estimate of CBF was possible in this study. Even if accurate normalization allowed an estimate of the effects of opioid agonism on CBF, further investigation would be required to determine if such agonism occurs within neural or vascular structures.2 Only then can we be certain that remifentanil truly produces "limbic system activation." We suggest that an alternative approach to dissociate the hypercapnia from the opioid agonist effects would be to perform studies over an equivalent CO2 range,3,4 or based on region of interest derived CO2 reactivity maps5,6 obtained in the same subjects.
REFERENCES
This article has been cited by other articles:
![]() |
W. A. Kofke, J. A. Detre, J. Wang, and P. A. Blissitt Remifentanil-Induced Cerebral Blood Flow Effects Anesth. Analg., January 1, 2008; 106(1): 347 - 348. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|